In other tumor types, such as lung [23] and ovarian cancer [24] a high mutational burden has a survival advantage in non-ICI treated patients, but in both instances has been attributed to DNA-repair deficiency primarily via BRCA1, BRCA2, or POLE genes. This evidence concerns the gene POLE and neoplasm.